A groundbreaking scientific investigation is challenging long-held assumptions about Alzheimer’s disease, suggesting that the neurological damage associated with this condition may not be irreversible. For over a century, the prevailing understanding of Alzheimer’s has painted it as a progressive ailment for which effective treatments focused primarily on mitigation and slowing advancement, rather than restoration of lost cognitive faculties. Despite substantial global investment and decades of intensive research, the landscape of therapeutic development has historically overlooked the possibility of reversing the disease’s effects, with no drug trials specifically designed with the explicit aim of recovering cognitive abilities. This paradigm is now undergoing a significant reevaluation, propelled by a collaborative effort involving researchers from University Hospitals, Case Western Reserve University, and the Louis Stokes Cleveland VA Medical Center. Their ambitious work endeavors to answer a pivotal question: can a brain already significantly impacted by advanced Alzheimer’s disease regain its former functionality?
At the core of this new research lies an exploration into the fundamental energy metabolism of brain cells, identifying a critical biological malfunction that appears to drive Alzheimer’s pathology. Published in the esteemed journal Cell Reports Medicine, the study, spearheaded by Dr. Kalyani Chaubey of the Pieper Laboratory, meticulously examined both human Alzheimer’s brain tissue samples and a variety of preclinical mouse models engineered to mimic the disease. The team’s findings pinpointed a profound deficit in the brain’s capacity to sustain adequate levels of Nicotinamide Adenine Dinucleotide (NAD+), a crucial molecule essential for cellular energy production and numerous vital biological processes. Their work demonstrates that maintaining optimal NAD+ balance is not only protective against the onset of Alzheimer’s but, more remarkably, can facilitate a reversal of the disease’s progression in experimental settings.
The natural aging process is accompanied by a gradual decline in NAD+ levels throughout the body, including within the brain. This reduction compromises the ability of cells to perform essential functions, ultimately impacting their survival. However, the researchers discovered that this decline is dramatically exacerbated in the brains of individuals afflicted with Alzheimer’s disease, a pattern that was consistently observed in the animal models utilized for the study. This heightened depletion of NAD+ in Alzheimer’s brains suggests a critical link between cellular energy failure and the neuropathological hallmarks of the disease.
To effectively study a condition that exclusively affects humans, scientists frequently employ specially developed mouse models that carry genetic mutations known to induce Alzheimer’s-like pathology. In this particular study, two distinct genetically modified mouse lines were utilized. One group harbored multiple human gene mutations associated with the abnormal processing of amyloid proteins, while the other carried a human mutation in the tau protein. Both amyloid and tau pathologies represent some of the earliest and most significant indicators of Alzheimer’s disease. In these engineered mice, the presence of these mutations triggered widespread neurodegeneration that closely mirrored the characteristics observed in human Alzheimer’s patients. This included disruptions to the blood-brain barrier, degeneration of neuronal fibers, chronic inflammatory responses, diminished neurogenesis (the creation of new neurons) in the hippocampus—a brain region vital for memory—compromised intercellular communication pathways, and extensive oxidative stress. Concurrently, these mice exhibited severe impairments in memory and cognitive abilities, mirroring the symptoms experienced by individuals with Alzheimer’s.
Following the confirmation of significantly reduced NAD+ levels in the brains of both human Alzheimer’s patients and the affected mouse models, the research team embarked on a critical investigation into two distinct therapeutic avenues. Their objective was to ascertain whether maintaining NAD+ balance prior to the manifestation of symptoms could serve as a preventative measure, and, more importantly, whether restoring this balance after the disease had already taken hold could lead to a reversal of the damage. This investigative approach builds upon prior findings from the same research group, previously published in the Proceedings of the National Academy of Sciences USA, which indicated that re-establishing NAD+ equilibrium could lead to both structural and functional recovery following severe and persistent traumatic brain injury. For the current study, the researchers employed P7C3-A20, a specialized pharmacological agent developed within the Pieper laboratory, designed to restore and maintain NAD+ homeostasis.
The outcomes of these experiments yielded exceptionally promising results. While maintaining NAD+ balance proved effective in preventing the development of Alzheimer’s pathology in the mice, the impact observed when treatment was initiated in animals with already advanced disease was particularly striking. In these cases, the restoration of NAD+ balance facilitated the brain’s intrinsic repair mechanisms, enabling it to mend the significant pathological damage previously inflicted by the genetic mutations. Across both mouse models, a complete recovery of cognitive function was observed. This functional recovery was further corroborated by serological markers, with blood tests revealing normalized levels of phosphorylated tau 217 (p-tau 217), a recently validated clinical biomarker now approved for the diagnosis of Alzheimer’s in human patients. These findings provide compelling evidence for disease reversal and offer a potential biomarker for future clinical applications in human trials.
Expressing a sentiment of cautious optimism, Dr. Andrew A. Pieper, the senior author of the study and Director of the Brain Health Medicines Center at the Harrington Discovery Institute at UH, conveyed his enthusiasm. "We were very excited and encouraged by our results," stated Dr. Pieper. "Restoring the brain’s energy balance achieved pathological and functional recovery in both lines of mice with advanced Alzheimer’s. Seeing this effect in two very different animal models, each driven by different genetic causes, strengthens the idea that restoring the brain’s NAD+ balance might help patients recover from Alzheimer’s." Dr. Pieper, who also holds distinguished professorial roles at UH and CWRU, and serves as a psychiatrist and investigator at the Louis Stokes VA Geriatric Research Education and Clinical Center, emphasized the significance of these findings.
The implications of this research suggest a potential paradigm shift in the future approach to managing Alzheimer’s disease. "The key takeaway is a message of hope—the effects of Alzheimer’s disease may not be inevitably permanent," Dr. Pieper remarked, underscoring the possibility that the damaged brain possesses a latent capacity for self-repair and functional recovery under specific therapeutic conditions. Dr. Chaubey elaborated on the study’s contribution, stating, "Through our study, we demonstrated one drug-based way to accomplish this in animal models, and also identified candidate proteins in the human AD brain that may relate to the ability to reverse AD."
It is crucial to distinguish this targeted therapeutic strategy from the ingestion of over-the-counter NAD+-precursor supplements. Dr. Pieper cautioned that while some animal studies have indicated that such supplements can elevate NAD+ levels, they may do so to potentially harmful extremes, even promoting cancer in some contexts. The methodology employed in this research relies on P7C3-A20, a pharmacological agent that facilitates cells in maintaining healthy NAD+ levels during periods of severe stress without pushing these levels beyond their normal physiological range. "This is important when considering patient care, and clinicians should consider the possibility that therapeutic strategies aimed at restoring brain energy balance might offer a path to disease recovery," Dr. Pieper advised.
This pioneering research not only offers a promising therapeutic avenue but also paves the way for subsequent investigations and, ultimately, clinical trials in human subjects. The technology developed from this work is currently being commercialized by Glengary Brain Health, a Cleveland-based company co-founded by Dr. Pieper. "This new therapeutic approach to recovery needs to be moved into carefully designed human clinical trials to determine whether the efficacy seen in animal models translates to human patients," Dr. Pieper explained, outlining the necessary next steps. Further laboratory research will focus on precisely identifying the specific components of brain energy balance most critical for recovery, evaluating complementary strategies for Alzheimer’s reversal, and exploring the potential efficacy of this recovery approach in other chronic, age-related neurodegenerative disorders.
About the Author
